Genmab — Juni 2018
-
Ok. Tak. Det er i hvert fald en god og opsummerende artikel. Sammen med folks hjælp herinde, så satte den lige et par ting på plads.
-
Jeg mener, at Jan tidligere har været ude med $13.
-
For mit eget vedkommende tænker jeg "better safe than sorry".
-
Bluebird Bio CAR-T delays multiple myeloma progression by one year, but is that enough?
By Adam Feuerstein
https://www.statnews.com/2018/06/01/bluebird-bio-car-t/ -
Daratumumab Plus Carfilzomib, Dexamethasone May Be Effective in Lenalidomide-Refractory Multiple Myeloma , cancertherapyadvisor, https://www.cancertherapyadvisor.com/asco-2018/multiple-myeloma-daratumumab-carfilzomib-dex-effective-treatment/article/770624/
-
Bernstein $CELG $BLUE: bb2121 #ASCO18 update in line with our expectations - 12m PFS not bad, but MRD negative not a cure http://www.twitlonger.com/show/n_1sqi5bt
-
-
Måske den har været linket? http://investor.bluebirdbio.com/static-files/d2659e1f-2219-4179-a24a-09a25b1660f6
-
Hver gang JDW skal præsentere hos GS nedjusterer de aktien........hvordan skal han tale den op af det hul? Salgstallene er det eneste der vil vise hvor stærk stoffet er i forhold til alle andre. Havde GS indkalkuleret 20% i solide?.......næh vel, de kører den ned på uvidenhed i markedet, gad vide hvad agendaen er? Casen har aldrig været mere solid, slet ikke når vi snart ser sc, et bud må være opover, målet er nok før sc rammer markedet for så kan succesen ikke skjules længere.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind